TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01614015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervision
Description: SAU consists of a 1-hour weekly group supervision session with the clinical team (typically 3-6 therapists). The on-site supervisor also conducts individual supervision sessions with each member of the clinical team. As such, the usual FFT supervision practice involves each therapist receiving two hours of supervision per week (one hour of group, one hour of individual). Supervision sessions are conducted by an on-site supervisor who has received intensive training in FFT supervision. The on-site supervisor also continues to receive feedback and guidance from a national consultant (FFT LLC) for one hour per month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Observational Supervision
Description: One intent of BOOST is to provide ongoing development of therapist clinical skills, and identify novel approaches to unique family circumstances that are consistent with FFT treatment. BOOST involves the BOOST supervisor reviewing the recorded therapy sessions prior to supervision sessions with the therapist and on-site FFT supervisor and weekly group and/or individual supervision meetings during which the BOOST supervisor provides feedback and coaching to the therapist. The goal of observation-based supervision is to ensure feedback to therapists is based on the supervisors' direct judgments about therapist behaviors, model adherence, and delivery of FFT services rather than relying solely on therapist self-report of session activities and interactions.
Study: NCT03094585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written and oral information
Description: The written information (booklet) was 12 A4 pages long and took about 15 minutes to read. The oral information consisted of group sessions which focused on active feedback. Each session was lead by one of the authors who first went through the topics described in the booklet. The review of the topics was followed by a plenary discussion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written information
Description: The written information (booklet) was 12 A4 pages long and took about 15 minutes to read.
Study: NCT04609657

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD)
Description: Beverage

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD)
Description: Beverage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD)
Description: Beverage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD)
Description: Beverage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD)
Description: Beverage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD)
Description: Beverage
Study: NCT02782741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa (GZ402666)
Description: Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alglucosidase alfa (GZ419829)
Description: Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
Study: NCT01997008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Positive Affect Skills Training
Study: NCT06280898

Intervention type: PROCEDURE
Intervention: Remote ischemic conditioning
Description: Remote ischemic condition
Study: NCT00325819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
Study: NCT02037477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium
Description: Rabeprazole sodium tablets
Study: NCT00325819

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
Study: NCT03615313

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 antibody expressing mesoCAR-T cells
Description: Patients with mesothelin positive cancer will be infused the PD-1 antibody expressing mesoCAR-T cells. The modified mesoCAR-T cells can specifically kill mesothelin positive cancer cells and secrete PD-1 antibody, which could enhance the cytotoxicity of mesoCAR-T cells and activate the tumor infiltrating lymphocytes.
Study: NCT03227718

Intervention type: BEHAVIORAL
Intervention: VOR and coordination measurements
Description: measurement of VOR and VOR suppression in addition to hand-eye coordination tasks

Intervention type: BEHAVIORAL
Intervention: VOR and coordination measurements
Description: measurement of VOR and VOR suppression in addition to hand-eye coordination tasks
Study: NCT01775007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brillouin Ocular Analyser
Description: Measurement of the local viscoelastic properties (Brillouin Shift) of the Anterior Eye Segment.
Study: NCT03656627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given as an IV infusion every two weeks, in an outpatient setting. One cycle is a 28-day period, with Nivolumab given on days 1 and 15 of a 28-day cycle.~For each cohort, all patients will be dosed at 240 mg IV. There will be no dose de-escalation or escalation from this dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given as an IV infusion every two weeks, in an outpatient setting. One cycle is a 28-day period, with Nivolumab given on days 1 and 15 of a 28-day cycle.~For each cohort, all patients will be dosed at 240 mg IV. There will be no dose de-escalation or escalation from this dose level.
Study: NCT04009265

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: adjuvant treatment
Description: adjuvant treatments include chemotherapy or chemoradiotherapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: adjuvant treatment
Description: adjuvant treatments include chemotherapy or chemoradiotherapy
Study: NCT01791595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3965
Description: Day -7: single dose of 5 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 5 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3965
Description: Day -7: single dose of 10 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3965
Description: Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 20 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3965
Description: Day -7: single dose of 30 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 30 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3965
Description: Day -7: single dose of 30 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 15 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3965
Description: Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3965
Description: Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment (first 3 trial participants in the Expansion Cohort only; subsequent patients started treatment at Cycle 1, Day 1).~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Study: NCT02037477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium
Description: Rabeprazole sodium tablets
Study: NCT00218231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg/day bupropion-sr
Description: 300 mg/day for 1 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0 mg/day bupropion-sr
Description: 0 mg/day bupropion-sr
Study: NCT01134224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: 0.4 U/kg body weight injected subcutaneously (under the skin) once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: 0.6 U/kg body weight injected subcutaneously (under the skin) once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: 0.8 U/kg body weight injected subcutaneously (under the skin) once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: 0.4 U/kg body weight injected subcutaneously (under the skin) once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: 0.6 U/kg body weight injected subcutaneously (under the skin) once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: 0.8 U/kg body weight injected subcutaneously (under the skin) once
Study: NCT04264377

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Bronchoscopy for retrieval of airway cells

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Bronchoscopy for retrieval of airway cells
Study: NCT04394377

Intervention type: DRUG
Group type: OTHER
Intervention: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed
Description: Routine full anticoagulation strategy

Intervention type: DRUG
Group type: OTHER
Intervention: Group 2: control group with enoxaparin 40mg/d
Description: Usual standard of care and currently have no indication of full anticoagulation.
Study: NCT03283540

Intervention type: PROCEDURE
Intervention: TaTME
Description: Low anterior resection of the rectum entails a sharp dissection circumferentially around the mesorectum in an avascular plane between the visceral and parietal layers of the endopelvic fascia in what is known as Total Mesorectal Excision. This dissection can be achieved transanally starting down in the pelvis and going up in what is known as Transanal Total Mesorectal Excision

Intervention type: PROCEDURE
Intervention: TME
Description: Low anterior resection of the rectum entails a sharp dissection circumferentially around the mesorectum in an avascular plane between the visceral and parietal layers of the endopelvic fascia in what is known as Total Mesorectal Excision. This surgery can also be done via an up-to-down approach beginning high in the abdomen and going low in the pelvis to achieve dissection around the mesorectum.
Study: NCT00378664

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar to sacral ventral nerve re-routing procedure
Description: surgical nerve re-routing procedure
Study: NCT02290808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Theory-based group
Description: Workbooks and mini-counselling sessions will be provided to participants in this group.
Study: NCT01049451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH
Description: Subjects assigned to the ACTH arm will receive ACTH (Acthar gel) as intramuscular (IM) injections once a day for 3 consecutive days on a monthly basis, for 12 consecutive months. The dosage of ACTH will be 80 units per injection, for a total of 240 units over the three day period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Subjects assigned to the MP arm will receive intravenous (IV) infusions of 1 gram of MP once a month for 12 months
Study: NCT05190783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Description: mixture of formalin, cresol and glycerine used for fixation of pulp tissues

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formocresol
Description: mixture of formalin, cresol and glycerine used for fixation of pulp tissues

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: material used for pulp regeneration, direct and indirect pulp capping

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: material used for pulp regeneration, direct and indirect pulp capping

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TheraCal
Description: light cured resin modified calcium silicate filled liner designed for use in direct and indirect pulp capping

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TheraCal
Description: light cured resin modified calcium silicate filled liner designed for use in direct and indirect pulp capping

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulpotomy
Description: removal of the carious tooth structure and unroofing of the pulp chamber with a round carbide bur with high speed and water spray. The coronal pulp tissue will be then removed using a #4 carbide bur with slow speed and sharp spoon excavator.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpotomy
Description: removal of the carious tooth structure and unroofing of the pulp chamber with a round carbide bur with high speed and water spray. The coronal pulp tissue will be then removed using a #4 carbide bur with slow speed and sharp spoon excavator.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulpotomy
Description: removal of the carious tooth structure and unroofing of the pulp chamber with a round carbide bur with high speed and water spray. The coronal pulp tissue will be then removed using a #4 carbide bur with slow speed and sharp spoon excavator.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: partial pulpotomy
Description: complete removal of caries till exposure occurs. The exposed surface of the pulp will be gently removed using a sterile round diamond bur and a high-speed, water-cooled handpiece with light hand pressure. The removal of the pulp did not exceed approximately two mm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: partial pulpotomy
Description: complete removal of caries till exposure occurs. The exposed surface of the pulp will be gently removed using a sterile round diamond bur and a high-speed, water-cooled handpiece with light hand pressure. The removal of the pulp did not exceed approximately two mm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: partial pulpotomy
Description: complete removal of caries till exposure occurs. The exposed surface of the pulp will be gently removed using a sterile round diamond bur and a high-speed, water-cooled handpiece with light hand pressure. The removal of the pulp did not exceed approximately two mm.
Study: NCT02686177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin or sulfonylurea
Study: NCT00218114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium
Description: Participants are titrated over 2 weeks, as tolerated to 10 mgs / pound, and blood levels are checked to determine that the blood level is between 50-110 micrograms / ml.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be on matching placebo.
Study: NCT00894205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strengthening exercise program
Description: A low intensity strengthening exercise program based on the Tufts University Strong Bones program. Utilizes small free weights and chair exercises. Participants attend community based class 2-3x/wk for 4 wks.
Study: NCT03224793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study: NCT00449618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100 mg
Description: dose of 100 mg administered on awakening or at bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100 mg
Description: dose of 100 mg administered on awakening or at bedtime

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Description: Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Description: Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Description: Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Description: Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chronotherapy, timing of medication
Description: Dosing on awakening versus bedtime

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chronotherapy, timing of medication
Description: Dosing on awakening versus bedtime

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Chronotherapy, timing of medication
Description: Dosing on awakening versus bedtime

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Chronotherapy, timing of medication
Description: Dosing on awakening versus bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of placebo on awakening versus bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of placebo on awakening versus bedtime
Study: NCT00979576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 M + Pemetrexed
Description: BIBF 1120 medium dose bid+ Pemetrexed 500 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 H + Pemetrexed
Description: BIBF 1120 high dose bid+ Pemetrexed 500 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 RD + Pemetrexed
Description: confirmed dose of BIBF 1120 bid + Pemetrexed 500 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 L + Pemetrexed
Description: BIBF 1120 low dose bid+ Pemetrexed 500 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 Placebo + Pemetrexed
Description: placebo BIBF 1120 bid + Pemetrexed 500 mg/m\^2
Study: NCT02535975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets metformin 500 mg PO three times a day for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets placebo PO three times a day for 24 weeks
Study: NCT03942484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rPMS device
Description: Pelvic floor muscle contractions will be induced by the device.
Study: NCT00703417

Intervention type: DEVICE
Intervention: magnetic Resonance Imaging
Description: MRI of the calcaneus, the distal tibia, the distal radius and also lower back.

Intervention type: DEVICE
Intervention: magnetic Resonance Imaging
Description: MRI of the calcaneus, the distal tibia, the distal radius and also lower back.

Intervention type: DEVICE
Intervention: magnetic Resonance Imaging
Description: MRI of the calcaneus, the distal tibia, the distal radius and also lower back.

Intervention type: DEVICE
Intervention: Computed Tomography
Description: CT scan of the lower back and hip

Intervention type: DEVICE
Intervention: Computed Tomography
Description: CT scan of the lower back and hip

Intervention type: DEVICE
Intervention: High resolution peripheral quantitative computed tomography
Description: HR-pQCT of the distal radius and distal tibia

Intervention type: DEVICE
Intervention: High resolution peripheral quantitative computed tomography
Description: HR-pQCT of the distal radius and distal tibia

Intervention type: DEVICE
Intervention: High resolution peripheral quantitative computed tomography
Description: HR-pQCT of the distal radius and distal tibia
Study: NCT04517097

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: one blood sample and one questionnaire to each patient and salaried staff included

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: one blood sample and one questionnaire to each patient and salaried staff included